Determination of the ability to drive and operate machines after single and multiple oral dose of Neramexane as compared to placebo
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
TRIPLE
Enrollment
64
tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
Merz Pharmaceuticals
Frankfurt am Main, Germany
Fitness to drive
Time frame: 15 days
Psychometric test and motor control tests
Time frame: 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.